Utah Medical Products, Inc. (UTMD) reported financial results for Q1 2025 that were consistent with its previously announced projections. The company experienced a 14.4% decrease in net sales, an 18.1% decrease in gross profit, an 18.8% decrease in operating income, a 23.1% decrease in net income, and a 16.0% decrease in EPS compared to Q1 2024. The decline was largely attributed to a significant drop in OEM sales to PendoTECH.

Utah Medical Products reported a decrease in revenue, net income, and EPS for Q4 2024 compared to the same period in 2023. The decline was attributed to lower sales across various segments, including OEM, OUS distributors, and Filshie devices. However, profit margins held up well due to cost management and a favorable shift in sales mix.

Utah Medical Products reported a decrease in revenue but an increase in net income margin for Q3 2024. Revenue was down 20% compared to Q3 2023, while net income decreased by 9.4%. Earnings per share decreased by 5.2% due to share repurchases and a lower income tax provision rate.

Utah Medical Products reported a decrease in Q4 revenues by 9.1% and a decrease in net income by 5.9%. EPS also decreased by 5.8%. The company's balance sheet remains strong with increased cash and investments.

Utah Medical Products reported a decrease in revenue and net income compared to the same quarter last year. Worldwide consolidated sales were down by 3.5%, and net income decreased by 8.1%. The decline was primarily attributed to lower biopharmaceutical OEM sales. However, OUS sales increased by 20.8%.

Utah Medical Products reported a decrease in revenue and operating income for the second quarter of 2023, but net income and earnings per share increased. The company's balance sheet remained strong with increased cash and investments.

Utah Medical Products, Inc. reported a 1.6% increase in revenues and a 19.2% increase in net income for the first quarter of 2023 compared to the same period in 2022. Earnings per share increased by 20.2%. The company's balance sheet remained strong with increased cash and investments.

Utah Medical Products reported a 5.1% increase in Q4 2022 revenues compared to Q4 2021, with net income rising by 10.3%. The company's EPS also increased by 11.2%. While domestic sales saw a decrease, OUS sales increased significantly, although these were impacted by stronger USD.

Utah Medical Products Inc. reported a 3% increase in revenues and a 1.8% increase in net income for Q3 2022 compared to Q3 2021, despite facing cost inflation, supply chain disruption, litigation expenses, and a stronger U.S. Dollar.

UTMD reported a 6.5% increase in sales and a 19.7% increase in net income compared to Q2 2021. The company benefited from strong OUS sales growth, better absorption of fixed IIA amortization expense and a reduction of foreign currency operating expenses due to a stronger USD.

Utah Medical Products reported a strong first quarter in 2022, with a 12.4% increase in revenues, a 16.3% increase in operating income, and a 16.9% increase in net income compared to the first quarter of 2021. The company's EPS also increased by 16.6%.

Utah Medical Products, Inc. reported a strong fourth quarter and year-end 2021, demonstrating a remarkable recovery compared to 2020. The company exceeded its objective to fully recover back to its 2019 financial performance, with consolidated sales up across all product categories for the year. Profit margins have returned to levels more consistent with longer-term management expectations, and the balance sheet continued to strengthen.

Utah Medical Products reported a strong recovery in Q3 2021, with revenues up 20% compared to Q3 2020 and a net income increase of 43.4%. The company exceeded its objective to recover back to its 2019 financial performance.

Utah Medical Products reported a significant increase in revenue, gross profit, and operating income compared to Q2 2020, which was the low point of performance during the COVID-19 pandemic. The company's financial results confirm that UTMD may be back on track after surviving a depression in its business in 2020.

Utah Medical Products reported a slight increase in revenue and gross profit for Q1 2021 compared to Q1 2020. Despite increased operating income, net income and earnings per share decreased due to lower non-operating income and a higher tax rate. The balance sheet continued to strengthen, with increased cash and investments.

Utah Medical Products reported its Q4 2020 financial results, showing a recovery from the COVID-19 depression with the best revenue quarter of the year, almost 2% higher than the pre-pandemic Q4 2019. However, net income decreased by 21.7% compared to Q4 2019.

Utah Medical Products reported a decrease in revenue for the third quarter of 2020 compared to the same period in 2019, primarily due to the impact of COVID-19 on medical procedures. However, U.S. domestic sales showed a substantial recovery from the previous quarter. The company's balance sheet remained strong with an absence of debt, and management focused on managing operating expenses while preserving resources for long-term growth.

Utah Medical Products Inc. reported a significant decrease in sales, gross profit, and net income for the second quarter of 2020 compared to the same period in 2019, primarily due to the COVID-19 pandemic's impact on elective medical procedures. Despite the challenges, the company maintained profitability and a solid financial position.

Utah Medical Products, Inc. reported a slight increase in revenues and gross profit for the first quarter of 2020 compared to the same period in 2019, but experienced a decrease in operating income due to higher amortization expenses and the impact of COVID-19 on elective surgeries.

Utah Medical Products reported a strong fourth quarter in 2019, with a 21.3% increase in revenues and a 28.5% increase in net income compared to the same period in 2018. The company benefited from direct sales of the Filshie Clip System and growth in OEM product sales. Earnings per share also saw a significant increase, reflecting the company's improved profitability.